Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials

Wayne C Levy; Dariush Mozaffarian; David T Linker; Kenneth W Kenyon; John G F Cleland; Michel Komajda; Willem J Remme; Christian Torp-Pedersen; Marco Metra; Philip A Poole-Wilson; COMET Investigators; Wayne C Levy; Dariush Mozaffarian; David T Linker; Kenneth W Kenyon; John G F Cleland; Michel Komajda; Willem J Remme; Christian Torp-Pedersen; Marco Metra; Philip A Poole-Wilson; COMET Investigators

doi:10.1093/eurjhf/hfn048

Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials

Wayne C Levy, Dariush Mozaffarian, David T Linker, Kenneth W Kenyon, John G F Cleland, Michel Komajda, Willem J Remme, Christian Torp-Pedersen, Marco Metra, Philip A Poole-Wilson, COMET Investigators, Wayne C Levy, Dariush Mozaffarian, David T Linker, Kenneth W Kenyon, John G F Cleland, Michel Komajda, Willem J Remme, Christian Torp-Pedersen, Marco MetraPhilip A Poole-Wilson, COMET Investigators

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

10 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009-Mar

Originalsprog	Engelsk
Tidsskrift	European Journal of Heart Failure
Vol/bind	11
Udgave nummer	3
Sider (fra-til)	256-63
Antal sider	8
ISSN	1388-9842
DOI	https://doi.org/10.1093/eurjhf/hfn048 https://doi.org/10.1093/eurjhf/hfn048
Status	Udgivet - 1 mar. 2009

Bibliografisk note

Keywords: Adrenergic beta-Antagonists; Carbazoles; Confidence Intervals; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meiers Estimate; Life Expectancy; Metoprolol; Odds Ratio; Propanolamines; Survival Rate; Time Factors; Treatment Outcome

Adgang til dokumentet

Citationsformater

Levy, W. C., Mozaffarian, D., Linker, D. T., Kenyon, K. W., Cleland, J. G. F., Komajda, M., Remme, W. J., Torp-Pedersen, C., Metra, M., Poole-Wilson, P. A., COMET Investigators, Levy, W. C., Mozaffarian, D., Linker, D. T., Kenyon, K. W., Cleland, J. G. F., Komajda, M., Remme, W. J., Torp-Pedersen, C., ... COMET Investigators (2009). Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. European Journal of Heart Failure, 11(3), 256-63. https://doi.org/10.1093/eurjhf/hfn048, https://doi.org/10.1093/eurjhf/hfn048

Levy, WC, Mozaffarian, D, Linker, DT, Kenyon, KW, Cleland, JGF, Komajda, M, Remme, WJ, Torp-Pedersen, C, Metra, M, Poole-Wilson, PA, COMET Investigators, Levy, WC, Mozaffarian, D, Linker, DT, Kenyon, KW, Cleland, JGF, Komajda, M, Remme, WJ, Torp-Pedersen, C, Metra, M, Poole-Wilson, PA & COMET Investigators 2009, 'Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials', European Journal of Heart Failure, bind 11, nr. 3, s. 256-63. https://doi.org/10.1093/eurjhf/hfn048, https://doi.org/10.1093/eurjhf/hfn048

@article{e183bb90785e11df928f000ea68e967b,

title = "Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials",

abstract = "AIMS: A standard metric to estimate absolute treatment effects is numbers-needed-to-treat (NNT), which implicitly assumes that all benefits reverse at trial-end. However, in-trial survival benefits typically do not reverse until long after trial-end, so that NNT will substantially underestimate lifetime benefits. METHODS AND RESULTS: We developed a new concept, years-needed-to-treat (YNT) to add 1 year of life, that quantifies the expected average life expectancy for two treatments including the estimated years of life remaining post-trial. Numbers-needed-to-treat and YNT were calculated in the COMET trial, in which carvedilol vs. metoprolol tartrate resulted in 17% lower mortality over 4.8 years. A multivariate Cox model was used to predict survival. Remaining years of life were estimated using the mortality-life-table method. At trial-end, survival was 9% higher in the carvedilol arm. Assuming that patients remained on the same therapy post-trial, the average total years of life for carvedilol vs. metoprolol were 10.63 +/- 0.19 vs. 9.48 +/- 0.18 (P < 0.0001) or 1.15 (95% confidence interval 0.64-1.66) additional years of life. The YNT was 9.2, indicating that 9.2 person-years of treatment added 1 person-year of life, compared with NNT of 59. CONCLUSION: Compared with NNT, the YNT method more accurately accounts for potential long-term benefits of interventions in randomized trials.",

author = "Levy, {Wayne C} and Dariush Mozaffarian and Linker, {David T} and Kenyon, {Kenneth W} and Cleland, {John G F} and Michel Komajda and Remme, {Willem J} and Christian Torp-Pedersen and Marco Metra and Poole-Wilson, {Philip A} and {COMET Investigators} and Levy, {Wayne C} and Dariush Mozaffarian and Linker, {David T} and Kenyon, {Kenneth W} and Cleland, {John G F} and Michel Komajda and Remme, {Willem J} and Christian Torp-Pedersen and Marco Metra and Poole-Wilson, {Philip A} and Torp-Pedersen, {Christian Tobias}",

note = "Keywords: Adrenergic beta-Antagonists; Carbazoles; Confidence Intervals; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meiers Estimate; Life Expectancy; Metoprolol; Odds Ratio; Propanolamines; Survival Rate; Time Factors; Treatment Outcome",

year = "2009",

month = mar,

day = "1",

doi = "10.1093/eurjhf/hfn048",

language = "English",

volume = "11",

pages = "256--63",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "JohnWiley & Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials

AU - Levy, Wayne C

AU - Mozaffarian, Dariush

AU - Linker, David T

AU - Kenyon, Kenneth W

AU - Cleland, John G F

AU - Komajda, Michel

AU - Remme, Willem J

AU - Torp-Pedersen, Christian

AU - Metra, Marco

AU - Poole-Wilson, Philip A

AU - COMET Investigators

AU - Levy, Wayne C

AU - Mozaffarian, Dariush

AU - Linker, David T

AU - Kenyon, Kenneth W

AU - Cleland, John G F

AU - Komajda, Michel

AU - Remme, Willem J

AU - Torp-Pedersen, Christian

AU - Metra, Marco

AU - Poole-Wilson, Philip A

AU - COMET Investigators

N1 - Keywords: Adrenergic beta-Antagonists; Carbazoles; Confidence Intervals; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meiers Estimate; Life Expectancy; Metoprolol; Odds Ratio; Propanolamines; Survival Rate; Time Factors; Treatment Outcome

PY - 2009/3/1

Y1 - 2009/3/1

N2 - AIMS: A standard metric to estimate absolute treatment effects is numbers-needed-to-treat (NNT), which implicitly assumes that all benefits reverse at trial-end. However, in-trial survival benefits typically do not reverse until long after trial-end, so that NNT will substantially underestimate lifetime benefits. METHODS AND RESULTS: We developed a new concept, years-needed-to-treat (YNT) to add 1 year of life, that quantifies the expected average life expectancy for two treatments including the estimated years of life remaining post-trial. Numbers-needed-to-treat and YNT were calculated in the COMET trial, in which carvedilol vs. metoprolol tartrate resulted in 17% lower mortality over 4.8 years. A multivariate Cox model was used to predict survival. Remaining years of life were estimated using the mortality-life-table method. At trial-end, survival was 9% higher in the carvedilol arm. Assuming that patients remained on the same therapy post-trial, the average total years of life for carvedilol vs. metoprolol were 10.63 +/- 0.19 vs. 9.48 +/- 0.18 (P < 0.0001) or 1.15 (95% confidence interval 0.64-1.66) additional years of life. The YNT was 9.2, indicating that 9.2 person-years of treatment added 1 person-year of life, compared with NNT of 59. CONCLUSION: Compared with NNT, the YNT method more accurately accounts for potential long-term benefits of interventions in randomized trials.

AB - AIMS: A standard metric to estimate absolute treatment effects is numbers-needed-to-treat (NNT), which implicitly assumes that all benefits reverse at trial-end. However, in-trial survival benefits typically do not reverse until long after trial-end, so that NNT will substantially underestimate lifetime benefits. METHODS AND RESULTS: We developed a new concept, years-needed-to-treat (YNT) to add 1 year of life, that quantifies the expected average life expectancy for two treatments including the estimated years of life remaining post-trial. Numbers-needed-to-treat and YNT were calculated in the COMET trial, in which carvedilol vs. metoprolol tartrate resulted in 17% lower mortality over 4.8 years. A multivariate Cox model was used to predict survival. Remaining years of life were estimated using the mortality-life-table method. At trial-end, survival was 9% higher in the carvedilol arm. Assuming that patients remained on the same therapy post-trial, the average total years of life for carvedilol vs. metoprolol were 10.63 +/- 0.19 vs. 9.48 +/- 0.18 (P < 0.0001) or 1.15 (95% confidence interval 0.64-1.66) additional years of life. The YNT was 9.2, indicating that 9.2 person-years of treatment added 1 person-year of life, compared with NNT of 59. CONCLUSION: Compared with NNT, the YNT method more accurately accounts for potential long-term benefits of interventions in randomized trials.

U2 - 10.1093/eurjhf/hfn048

DO - 10.1093/eurjhf/hfn048

M3 - Journal article

C2 - 19164422

SN - 1388-9842

VL - 11

SP - 256

EP - 263

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 3

ER -